LPAR5 and prostate adenocarcinoma: After analyzing the expression levels of LPAR5 in the three clinicopathological features, we can draw the following conclusions: in terms of age, LUAD, PAAD, PRAD, and UVM were significantly different among different age groups (Fig. 5C).